FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039182015> ?p ?o ?g. }

• W2039182015 endingPage "302" @default.
• W2039182015 startingPage "297" @default.
• W2039182015 abstract "To compare patient tolerance and treatment efficacy of subcutaneous interferon (IFN) alpha 2a plus cryotherapy versus cryotherapy alone in treatment of primary anogenital (AG) warts.Randomised placebo controlled observer blind study. Statistical analysis was by chi square and Mann Whitney U tests.60 patients with newly diagnosed AG warts.29 and 31 patients were treated with subcutaneous IFN alpha 2a plus cryotherapy or placebo injections plus cryotherapy, respectively.Clinical presence or absence of AG warts. Patients wart-free at 8 weeks were asked to re-attend at 12 weeks; those with persistent warts at 8 weeks were withdrawn from the study.At 8 weeks 60.7% (17/28 patients) of the IFN group and 67.9% (19/28 patients) of the placebo group were clinically wart-free (not significant); corresponding figures at 12 week review were 29.6% (8/27 patients) and 40% (10/25 patients) respectively (not significant). There was no difference in treatment response between males and females. Recurrence of warts at three month review, in patients cleared of warts at 8 weeks, was seen in 50% (8/16) and 37.5% (6/16) of patients in the IFN and placebo groups respectively (not significant). Multiple warts and the presence of perianal/anal canal warts, either alone or concurrent with warts on the genitalia, at first clinic attendance, were adverse prognostic indicators (p less than 0.001, and p = 0.05 respectively). Cervical human papilloma virus (HPV) infection, exophytic or subclinical, was present in 58.3% and 77.2% of females in the IFN and placebo groups respectively, at trial entry. Although these lesions were not directly treated, colposcopic resolution was seen in 12.5% of affected women, in both treatment groups, by the end of the 7 week treatment period. Systemic side effects were significantly more common in the IFN than in the placebo group, 50% versus 10.7% of patients (p less than 0.01). Severe influenza like symptoms occurred, after the first three injections only, in one patient treated with IFN; all other reported side effects were mild.Subcutaneous IFN alpha 2a combined with cryotherapy is no more effective than cryotherapy alone in the treatment of primary AG warts. The presence of multiple warts and perianal/anal canal warts are adverse prognostic indicators." @default.
• W2039182015 created "2016-06-24" @default.
• W2039182015 creator A5011573082 @default.
• W2039182015 creator A5016252150 @default.
• W2039182015 creator A5022312109 @default.
• W2039182015 creator A5034517887 @default.
• W2039182015 creator A5081958751 @default.
• W2039182015 date "1991-08-01" @default.
• W2039182015 modified "2023-09-25" @default.
• W2039182015 title "Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study." @default.
• W2039182015 cites W109449622 @default.
• W2039182015 cites W1974361668 @default.
• W2039182015 cites W1976226568 @default.
• W2039182015 cites W1989392259 @default.
• W2039182015 cites W1991078640 @default.
• W2039182015 cites W1993653373 @default.
• W2039182015 cites W2001076841 @default.
• W2039182015 cites W2001759565 @default.
• W2039182015 cites W2002606132 @default.
• W2039182015 cites W2015102014 @default.
• W2039182015 cites W2026537441 @default.
• W2039182015 cites W2029138627 @default.
• W2039182015 cites W2049156013 @default.
• W2039182015 cites W2062896803 @default.
• W2039182015 cites W2063526400 @default.
• W2039182015 cites W2064522642 @default.
• W2039182015 cites W2066077006 @default.
• W2039182015 cites W2071906475 @default.
• W2039182015 cites W2072260598 @default.
• W2039182015 cites W2085065185 @default.
• W2039182015 cites W2113679638 @default.
• W2039182015 cites W2120600949 @default.
• W2039182015 cites W2127962592 @default.
• W2039182015 cites W2138170781 @default.
• W2039182015 cites W2141809669 @default.
• W2039182015 cites W2142663842 @default.
• W2039182015 cites W2144529000 @default.
• W2039182015 cites W2145171774 @default.
• W2039182015 cites W2146947992 @default.
• W2039182015 cites W2322400240 @default.
• W2039182015 cites W2326242884 @default.
• W2039182015 cites W2394616377 @default.
• W2039182015 cites W2396265164 @default.
• W2039182015 cites W2404114139 @default.
• W2039182015 cites W2410595571 @default.
• W2039182015 cites W2411518716 @default.
• W2039182015 cites W2417109374 @default.
• W2039182015 cites W2417969855 @default.
• W2039182015 cites W2419310763 @default.
• W2039182015 cites W2428587651 @default.
• W2039182015 cites W2440040950 @default.
• W2039182015 cites W4211140299 @default.
• W2039182015 cites W4238631395 @default.
• W2039182015 cites W4238646593 @default.
• W2039182015 cites W4290356921 @default.
• W2039182015 cites W4300315491 @default.
• W2039182015 cites W4301157156 @default.
• W2039182015 cites W48207142 @default.
• W2039182015 doi "https://doi.org/10.1136/sti.67.4.297" @default.
• W2039182015 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1194704" @default.
• W2039182015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1916791" @default.
• W2039182015 hasPublicationYear "1991" @default.
• W2039182015 type Work @default.
• W2039182015 sameAs 2039182015 @default.
• W2039182015 citedByCount "20" @default.
• W2039182015 countsByYear W20391820152012 @default.
• W2039182015 countsByYear W20391820152014 @default.
• W2039182015 countsByYear W20391820152016 @default.
• W2039182015 countsByYear W20391820152017 @default.
• W2039182015 countsByYear W20391820152019 @default.
• W2039182015 crossrefType "journal-article" @default.
• W2039182015 hasAuthorship W2039182015A5011573082 @default.
• W2039182015 hasAuthorship W2039182015A5016252150 @default.
• W2039182015 hasAuthorship W2039182015A5022312109 @default.
• W2039182015 hasAuthorship W2039182015A5034517887 @default.
• W2039182015 hasAuthorship W2039182015A5081958751 @default.
• W2039182015 hasBestOaLocation W20391820151 @default.
• W2039182015 hasConcept C113280763 @default.
• W2039182015 hasConcept C121608353 @default.
• W2039182015 hasConcept C126322002 @default.
• W2039182015 hasConcept C141071460 @default.
• W2039182015 hasConcept C142724271 @default.
• W2039182015 hasConcept C159047783 @default.
• W2039182015 hasConcept C168563851 @default.
• W2039182015 hasConcept C204243189 @default.
• W2039182015 hasConcept C204787440 @default.
• W2039182015 hasConcept C27081682 @default.
• W2039182015 hasConcept C2776178377 @default.
• W2039182015 hasConcept C2778220009 @default.
• W2039182015 hasConcept C2778308922 @default.
• W2039182015 hasConcept C2780149145 @default.
• W2039182015 hasConcept C2909179924 @default.
• W2039182015 hasConcept C71924100 @default.
• W2039182015 hasConcept C90924648 @default.
• W2039182015 hasConceptScore W2039182015C113280763 @default.
• W2039182015 hasConceptScore W2039182015C121608353 @default.
• W2039182015 hasConceptScore W2039182015C126322002 @default.
• W2039182015 hasConceptScore W2039182015C141071460 @default.

• next